Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment in 2025
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Rogers recent purchase
View:
Post by jicoop on Feb 02, 2021 10:32pm

Rogers recent purchase

Sorry if this was already posted, may not have seen it, but Roger back buying again, now owns 7,235,587 shares , sorry for the formatting , bought on Jan 28 . :


Issuer Name
Theralase Technologies Inc.
Insider Name
Dumoulin-White, Roger John
Relationship as filed with regulators
3 - 10% Security Holder of Issuer,4 - Director of Issuer,5 - Senior Officer of Issuer
Transaction ID
3669538
Filing Date
Jan 28, 2021
Transaction Date
Jan 28, 2021
Security Type
Common Shares
Transaction Nature
10 - Acquisition or disposition in the public market
Ownership Type
Direct Ownership
Registered Holder
 
# or Value Acquired or Disposed of
45,500
Unit Price or Exercise Price
$0.220
Closing Balance
7,235,587
Conversion or Exercise Price
0.000
Date of Expiry or Maturity
 
Underlying Security Designation
 
Comment by VentureGuy24 on Feb 02, 2021 10:45pm
How does he have so many shares!?!? Didnt the regulators take those shares away from him for fraudulent activity?
Comment by blackjack0 on Feb 03, 2021 8:22am
Venture amazing how guys like you can spin something quite positive to a question. What are you suggesting 
Comment by Longholder99 on Feb 03, 2021 8:40am
As i was using my ignore button i was reminded of RW taking keyboard warriors to court for comments like that. Winning a judgment. Interesting choice.
Comment by blackjack0 on Feb 03, 2021 8:43am
Longholder I was thinking exactly that. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed in 2025, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250